Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Corporate Update (March 2026)
38 slides from Century Therapeutics's corporate update, Mar 12, 2026
Slide 1: Unlocking the Value of our Pipeline for T1D
Unlocking the Value of our Pipeline for T1D March 2026
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts
Slide 3: Century Therapeutics Today
Cell Foundry and Allo-Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2026 3 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet cell
Slide 4: Century pipeline focus on Type 1 Diabetes and other autoimmune disease
4 Century pipeline focus on Type 1 Diabetes and other autoimmune disease Allo-Evasion engineered in all programs infusions in outpatient setting 1. Agreement in place for an investigator sponsored trial (IST) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen
Slide 5: Century Executive Team
5 Century Executive Team Experienced leadership with a track record of driving innovation and success in cell therapy Chad Cowan, PhD Chief Scientific Officer Brent Pfeiffenberger, PharmD, MBA Chairman and Chief Executive Officer Greg Russotti, PhD Chief Technology and Manufacturing Officer Megan Bi
Slide 6: Century Therapeutics
CENTURY THERAPEUTICS
Slide 7: Century is a leader in immune evasion engineering
7 Continued evolution to enhance holistic protection from major immunity pathways Century is a leader in immune evasion engineering Allo-Evasion 1.0 Deletion of HLA-I Deletion of HLA-II Insertion of HLA-E Protection from: Native T-cells Native NK-cells Humoral immunity CNTY-101 Deletion of HLA-I Del
Slide 8: Allo-Evasion 5.0: CD300a TASR ligand protection from host NK cells
8 Allo-EvasionTM 5.0: The CD300a TASR ligand has been shown to provide broad protection from host NK cells Male Female <50 >50 Gender Age Ethni-city CMV Caucasian Other African American Hispanic Negative Positive N = 45 PBMC Donors 0.01 0.1 1 0 0 .0 1 0 .1 1 0 25 50 75 100 0 E:T Ratio T Cell Surviva
Slide 9: Immunoglobulin degrading protease protects T cells from rejection
9 Immunoglobulin degrading protease As a result, Century’s T cells have been shown to be protected from rejection in preclinical CDC, ADCC and ADCP assays Century T cells have been shown to stably express IDP, an enzyme that cleaves off IgGs below the hinge, releasing the Fc fragment Allo-EvasionTM
Slide 10: Type 1 Diabetes Program
Type 1 Diabetes Program
Slide 11: Century is uniquely positioned to deliver a successful T1D cell replacement therapy
11 Century is uniquely positioned to deliver a successful T1D cell replacement therapy • T1D is a significant global market (9M pts WW) with high unmet medical need1 • Beta islet cell replacement for T1D has clear, validated clinical Proof-of-Concept (POC) over 20+ years2 • Transformational outcomes
Slide 12: Significant unmet need in Type 1 Diabetes
12 Significant unmet need in Type 1 Diabetes (T1D) Despite insulin therapy, people living with T1D face a high risk of life-limiting complications ~9 million people worldwide living with T1D1 Lifetime economic burden of T1D (US) estimated at~$813 billion2 T1D is associated with serious comorbidities
Slide 13: Beta Islet cell transplantation provides a potentially curative therapy in T1D
13 Beta Islet cell transplantation provides a potentially curative therapy in T1D Cell supply and chronic immunosuppression are major limitations In T1D, beta cells are destroyed Healthy islet beta cells produce insulin (green) In T1D, beta cells are destroyed Insulin independence achieved for one y
Slide 14: Stem-cell derived islets have restored physiologic islet function
14 Stem-cell (SC) derived islets have demonstrated the ability to restore physiologic islet function Demonstrates function and scale, but still requires chronic immunosuppression Zimislecel (VX-880) is a SC-derived insulin producing islet cell therapy3 10/12 patients receiving SC-derived islets were
Slide 15: CNTY-813: Century's Beta Islets with Allo-Evasion 5.0
15 CNTY-813: Century’s Beta Islets with Allo-Evasion 5.0 Uniquely positioned to potentially deliver a successful T1D cell replacement therapy • Glucose control in patients is important for resolving disease and reducing consequences of uncontrolled glucose • A scalable drug product enables broader p
Slide 16: CNTY-813 Scalable Generation of Beta Islets with Allo-Evasion 5.0
16 A fully scalable, bioreactor-enabled differentiation process yields mature, functional beta Islets from engineered iPSCs Clinical candidate selected with Century’s Allo-Evasion 5.0 to protect cells from immune rejection In vitro and in vivo data support potential to provide functional cure withou
Slide 17: Generation of Beta Islets with a 29 day defined multi-stage process
17 iPSC Definitive Endoderm Primitive Gut Tube Pancreatic Progenitor I Pancreatic Progenitor II Endocrine β Cell Generation of Beta Islets with a 29 day, Defined, Multi-stage Process Adapted to a Scalable Bioreactor Suspension System iPSC DE PGT PP1 PP2 EN β Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 S
Slide 18: Beta-islet differentiation process is reproducible across batches
18 Century beta-islet differentiation process is reproducible across batches High Purity Throughout the Differentiation Stage 1: Definitive Endoderm Stage 4: Pancreatic Endoderm Stage 6: Islet Endocrine Stage 6: Beta Cell Success Criteria: set by literature review of necessary purity to ensure a saf
Slide 19: CNTY-813 Beta Islets are highly potent
19 CNTY-813 Beta Islets are highly potent Potency Total Insulin Content Glucose-Stimulated Insulin Secretion Stimulation Index iPSC-Beta Islets Primary Islets 0 10000 20000 30000 40000 uIU Insulin/ 1E6 Cells 2mM Glucose 20mM Glucose iPSC-Beta Islets Primary Islets 0 5 10 15 Glucose Stimualtion Index
Slide 20: CNTY-813 comprises terminally differentiated endocrine cells
20 CNTY-813 comprises terminally differentiated endocrine cells Cell Cycle Analysis of Stage 6 CNTY-813 cells Cell Cycle Progression Analysis by Differentiation Stage Diff. Stage: iPSC 1 2 3 4 5 6 Post-mitotic β-islets with no cell proliferation MKI67 gene expression Cell cycle stage Source: Company
Slide 21: CNTY-813 Beta Islets rapidly restored normoglycemia in STZ-rendered T1D mice
21 CNTY-813 Beta Islets rapidly restored normoglycemia in STZ-rendered T1D mice Century Beta Islets Persisted and Controlled Glucose for >6 Months Non-Fasted Blood Glucose Century iPSC Beta Islets (unedited) Century iPSC Beta Islets with Allo-Evasion 5.0 -20 0 20 40 60 80 100120140160180200220 0 100
Slide 22: CNTY-813 restores normoglycemia upon a Glucose Tolerance Test
22 CNTY-813 observed to restore normoglycemia upon a Glucose Tolerance Test (GTT) Upon a GTT, normoglycemia is rescued within 60 minutes in both Unedited and Allo 5.0 Beta islet txp mice 12-week 0 10,000 20,000 30,000 40,000 AUC Diabetic Control: n=5 Unedited CNTY Beta Islets: n=3 Allo 5.0 CNTY Beta
Slide 23: CNTY-813 grafts comprised of endocrine cells with no outgrowths
23 CNTY-813 grafts observed to be comprised of endocrine cells with no evidence of outgrowths Blood Sugar Regulation Cell Division Glucagon Insulin Ki67 • 5M islets injected into murine kidney capsule – STZ treatment abrogated mouse insulin production – Mouse was normoglycemic within 30 days post-in
Slide 24: Allo-Evasion 5.0 protects CNTY-813 Beta Islets
24 Allo-Evasion 5.0 protects CNTY-813 Beta Islets Protection of Beta Islets • NK protection • ADCC protection Allo-Evasion 5.0 on Beta Islets • Elimination of HLA-I and II expression • Confirmed expression of Transgenes Count Normalized to Mode HLA Class I HLA Class II IdeS CD300a-TASR T Cell Evasio
Slide 25: Scalable manufacturing of cryopreserved Beta Islets
25 Scalable manufacturing of cryopreserved Beta Islets Suspension-Based iPSC Differentiation to Cryopreserved Beta Islets Permit Scalable Clinical Manufacturing Scalable iPSC Differentiation Platform Cryopreserved Century Beta Islets Single Dose Clinical Administration 3-80L+ PBS (or Stirred Tank) B
Slide 26: Autoimmune Disease Programs
Autoimmune Disease Programs
Slide 27: Addressing unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells
27 Addressing significant unmet need in autoimmunity with allogeneic CAR iT and CAR iNK cells • Limited but encouraging POC data2 with CAR-NK therapy support continued development in autoimmune disease • CARAMEL IST with CNTY-101 currently enrolling patients across four indications • Autologous CAR
Slide 28: CNTY-308 CD4+/CD8+ αβ iT-cell with Allo-Evasion 5.0
CNTY-308 CD4+/CD8+ αβ iT-cell with Allo-Evasion 5.0
Slide 29: CNTY-308 is an iPSC-derived CD19-targeted CAR-iT for B-cell-mediated disease
29 CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for B-cell-mediated disease CNTY-308 CD4+/CD8+ αβ iT-cell • CD19-targeted CAR to target B-cells for cytotoxic depletion – 4-1BB and CD3z co-stim domain to stimulate expansion on target engagement • Allo-Evasion 5.0 edits designed to includ
Slide 30: iPSC-derived CAR-αβT cells comparable to primary CAR-T cells
30 Function 1’ CAR-T CNTY-308 IL-2 secretion (pg/mL) ~3,000 ~2,000 Requires exogenous IL-2/IL-15 No No Repeat killing (rounds) >10 >10 Persistence in blood (days) 32 32 Tumor control after rechallenge (in vivo) Yes Yes CNTY–308 and 1’ CAR-T • Self-supports with own target-mediated IL-2 • High functi
Slide 31: Century iPSC-CAR-T cells controlled tumors and persisted in animal studies
31 In preclinical animal studies, Century iPSC-CAR-T cells controlled tumors, persisted for ≥1 month, and retained cytotoxic capacity upon rechallenge • Disseminated Nalm6 model (1e5 cells infused) • Effectors added 3 days post-tumor infusion • 1’ CAR-T dose: 5e6 cells • iPSC-CAR-T dose: 30e6 cells
Slide 32: CNTY-101 CAR-iNK cell therapy with Allo-Evasion
CNTY-101 CAR-iNK cell therapy with Allo-Evasion
Slide 33: CNTY-101 clinical program progressing in CARAMEL Phase 1/2 IST
33 CNTY-101 clinical program progressing in CARAMEL Phase 1/2 IST Key Inclusion Criteria: • Participants with moderate to severe SLE, LN, IIM, or dcSSc with treatment-resistant and active disease, after 2+ standard immunosuppressive therapies Key Endpoints: • Safety and tolerability, disease activit
Slide 34: Preliminary Data from the Erlangen CARAMEL Basket Trial
34 Preliminary Data from the Erlangen CARAMEL Basket Trial Preliminary Data Summary 0 20 40 60 0.0 0.5 1.0 1.5 0 20 40 60 0.00 0.05 0.10 0.15 CD19 Pre-CNTY-101 Day 19 Summary N=4 pts dosed Peripheral Blood Lymph Node • 4 patients dosed with CNTY-101 and IL-2 (SLE, IIM, SSc; failed median 7 treatment
Slide 35: Century Therapeutics
CENTURY THERAPEUTICS
Slide 36: Established in-house manufacturing from development to launch
36 Established in-house manufacturing from development to launch Quality product at disruptive scale and cost of goods • Built-for-purpose 53,000 ft2 cGMP facility • Produced and released clinical product for US and EU • Key leaders each with 1–2 decades of cell therapy manufacturing expertise, from
Slide 37: Century Therapeutics Today
Cell Foundry and Allo-Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2026 37 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet cel
Slide 38: Century Therapeutics
CENTURY THERAPEUTICS